Last reviewed · How we verify
Clinique Neuro-Outaouais — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| efgartigimod administration | efgartigimod administration | phase 3 | Monoclonal antibody | FcRn | Autoimmune diseases |
Therapeutic area mix
- Autoimmune diseases · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Alexion Pharmaceuticals, Inc. · 1 shared drug class
- Amgen · 1 shared drug class
- Arbeitsgemeinschaft medikamentoese Tumortherapie · 1 shared drug class
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- Azienda Ospedaliera Universitaria Integrata Verona · 1 shared drug class
- Baxalta now part of Shire · 1 shared drug class
- Bayer · 1 shared drug class
- AgeneBio · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Clinique Neuro-Outaouais:
- Clinique Neuro-Outaouais pipeline updates — RSS
- Clinique Neuro-Outaouais pipeline updates — Atom
- Clinique Neuro-Outaouais pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Clinique Neuro-Outaouais — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/clinique-neuro-outaouais. Accessed 2026-05-17.